デング熱ワクチン市場レポート：2030年までの動向、予測、競合分析

デング熱ワクチンの動向と予測

世界のデング熱ワクチン市場は、2024年から2030年までのCAGRが12.1%で、2030年までに推定11億米ドルに達すると予測されます。この市場の主な促進要因は、デング熱の流行が拡大していることと、世界中でワクチン開発の研究開発活動が活発化していることです。世界のデング熱ワクチン市場の将来は、病院、在宅医療、専門クリニックの各市場における機会によって有望視されています。

デング熱ワクチン市場の洞察

Lucintelの予測では、デングワクチン接種後に起こるようなアレルギー反応の治療や予防に広く使用されるため、抗アレルギー剤が予測期間中に最も高い成長を遂げる見込みです。

同市場では、予防接種を含むヘルスケアサービスの増加、予防医療への関心の高まり、より質の高いヘルスケアサービスの必要性から、病院が引き続き最大セグメントとなります。

アジア太平洋は、同地域におけるより良いヘルスケア・インフラ整備のための政府支出の増加により、予測期間中に最も高い成長が見込まれています。

本レポートでは、以下の11の主要な質問に回答している：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のデング熱ワクチン市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のデング熱ワクチン市場動向（2018～2023年）と予測（2024～2030年）
• タイプ別の世界のデング熱ワクチン市場
  • 弱毒生ワクチン
  • キメラ弱毒化生ワクチン
  • 不活生化ワクチン
  • サブユニットワクチン
  • 核酸ベースワクチン
• 治療別の世界のデング熱ワクチン市場
  • 利尿
  • 抗アレルギー剤
  • 血液希釈剤
  • その他
• 流通チャネル別の世界のデング熱ワクチン市場
  • 病院薬局
  • オンライン薬局
  • 小売薬局
• 最終用途別の世界のデング熱ワクチン市場
  • 病院
  • ホームケア
  • 専門クリニック
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のデング熱ワクチン市場
• 北米のデング熱ワクチン市場
• 欧州のデング熱ワクチン市場
• アジア太平洋デング熱ワクチン市場
• その他地域デング熱ワクチン市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • タイプ別の世界のデング熱ワクチン市場の成長機会
  • 治療法別の世界のデング熱ワクチン市場の成長機会
  • 流通チャネル別の世界のデング熱ワクチン市場の成長機会
  • 最終用途別の世界のデング熱ワクチン市場の成長機会
  • 地域別の世界のデング熱ワクチン市場の成長機会
• 世界のデング熱ワクチン市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のデング熱ワクチン市場の生産能力拡大
  • 世界のデング熱ワクチン市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Mylan
• BIO-MED
• Teva Pharmaceutical
• Sanofi
• Novartis
• GSK
• F. Hoffmann-La Roche

Dengue Vaccine Trends and Forecast

The future of the global dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 12.1% from 2024 to 2030. The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

A more than 150-page report is developed to help in your business decisions.

Dengue Vaccine by Segment

The study includes a forecast for the global dengue vaccine by type, treatment, distribution channel, end use, and region.

Dengue Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Live Attenuated Vaccine
• Chimeric Live Attenuated Vaccine
• Inactivated Vaccine
• Subunit Vaccine
• Nucleic Acid Based Vaccine

Dengue Vaccine Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

• Diuretic
• Anti-Allergic
• Blood Thinners
• Others

Dengue Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Dengue Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Dengue Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Dengue Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dengue vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dengue vaccine companies profiled in this report include-

• Mylan
• BIO-MED
• Teva Pharmaceutical
• Sanofi
• Novartis
• GSK
• F. Hoffmann-La Roche

Dengue Vaccine Market Insights

Lucintel forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.

Within this market, hospital will remain the largest segment due to increasing healthcare services including immunizations and growing focus towards preventative care and need for higher-quality healthcare services.

APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Features of the Global Dengue Vaccine Market

Market Size Estimates: Dengue vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Dengue vaccine market size by various segments, such as by type, treatment, distribution channel, end use, and region in terms of ($B).

Regional Analysis: Dengue vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatments, distribution channels, end uses, and regions for the dengue vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dengue vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the dengue vaccine market size?

Answer: The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030.

Q.2 What is the growth forecast for dengue vaccine market?

Answer: The global dengue vaccine market is expected to grow with a CAGR of 12.1% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the dengue vaccine market?

Answer: The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

Q4. What are the major segments for dengue vaccine market?

Answer: The future of the dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q5. Who are the key dengue vaccine market companies?

Answer: Some of the key dengue vaccine companies are as follows:

• Mylan
• BIO-MED
• Teva Pharmaceutical
• Sanofi
• Novartis
• GSK
• F. Hoffmann-La Roche

Q6. Which dengue vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.

Q7. In dengue vaccine market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dengue vaccine market by type (live attenuated vaccine, chimeric live attenuated vaccine, inactivated vaccine, subunit vaccine, and nucleic acid based vaccine), treatment (diuretic, anti-allergic, blood thinners, and others), distribution channel (hospital pharmacy, online pharmacy, and retail pharmacy), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dengue Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Dengue Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Dengue Vaccine Market by Type
  • 3.3.1: Live Attenuated Vaccine
  • 3.3.2: Chimeric Live Attenuated Vaccine
  • 3.3.3: Inactivated Vaccine
  • 3.3.4: Subunit Vaccine
  • 3.3.5: Nucleic Acid Based Vaccine
• 3.4: Global Dengue Vaccine Market by Treatment
  • 3.4.1: Diuretic
  • 3.4.2: Anti-Allergic
  • 3.4.3: Blood Thinners
  • 3.4.4: Others
• 3.5: Global Dengue Vaccine Market by Distribution Channel
  • 3.5.1: Hospital Pharmacy
  • 3.5.2: Online Pharmacy
  • 3.5.3: Retail Pharmacy
• 3.6: Global Dengue Vaccine Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Homecare
  • 3.6.3: Specialty Clinics
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Dengue Vaccine Market by Region
• 4.2: North American Dengue Vaccine Market
  • 4.2.1: North American Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
  • 4.2.2: North American Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.3: European Dengue Vaccine Market
  • 4.3.1: European Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
  • 4.3.2: European Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.4: APAC Dengue Vaccine Market
  • 4.4.1: APAC Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
  • 4.4.2: APAC Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.5: ROW Dengue Vaccine Market
  • 4.5.1: ROW Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
  • 4.5.2: ROW Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Dengue Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Dengue Vaccine Market by Treatment
  • 6.1.3: Growth Opportunities for the Global Dengue Vaccine Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Dengue Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Dengue Vaccine Market by Region
• 6.2: Emerging Trends in the Global Dengue Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Dengue Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dengue Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Mylan
• 7.2: BIO-MED
• 7.3: Teva Pharmaceutical
• 7.4: Sanofi
• 7.5: Novartis
• 7.6: GSK
• 7.7: F. Hoffmann-La Roche